New beginnings for matrix metalloproteinase inhibitors: identification of high-affinity zinc-binding groups
- PMID: 15237990
- DOI: 10.1021/ja0485513
New beginnings for matrix metalloproteinase inhibitors: identification of high-affinity zinc-binding groups
Abstract
In an effort to identify promising non-hydroxamate inhibitors of matrix metalloproteinases (MMPs), several new zinc-binding groups (ZBGs) based on pyrone, pyrothione, hydroxypyridinone, and hydroxypyridinethione chelators have been examined. Structural studies with tris(pyrazolyl)borate model complexes show that these ligands bind to the MMP active site zinc(II) ion in a bidentate fashion, similar to that found with hydroxamate-based inhibitors. Fluorescence- and colorimetric-based enzyme assays have been used to determine the IC50 values for these ZBGs against MMP-3; mixed O,S-donor ligands were found to be remarkably potent, with IC50 values as much as 700-fold lower than that found for acetohydroxamic acid. Inhibitory activity was found to parallel metal binding affinity as determined in titrations with model complexes. These results demonstrate that MPIs based on new ZBGs are feasible and may indeed improve the overall performance of inhibitors designed against these important medicinal targets.
Similar articles
-
A new role for old ligands: discerning chelators for zinc metalloproteinases.J Am Chem Soc. 2006 Mar 15;128(10):3156-7. doi: 10.1021/ja057957s. J Am Chem Soc. 2006. PMID: 16522091
-
Potent, selective pyrone-based inhibitors of stromelysin-1.J Am Chem Soc. 2005 Oct 19;127(41):14148-9. doi: 10.1021/ja054558o. J Am Chem Soc. 2005. PMID: 16218585
-
Examination of novel zinc-binding groups for use in matrix metalloproteinase inhibitors.Inorg Chem. 2003 Jun 2;42(11):3423-30. doi: 10.1021/ic026029g. Inorg Chem. 2003. PMID: 12767177
-
A bioinorganic perspective on matrix metalloproteinase inhibition.Curr Top Med Chem. 2004;4(15):1551-73. doi: 10.2174/1568026043387368. Curr Top Med Chem. 2004. PMID: 15579096 Review.
-
Third generation of matrix metalloprotease inhibitors: Gain in selectivity by targeting the depth of the S1' cavity.Biochimie. 2010 Nov;92(11):1501-8. doi: 10.1016/j.biochi.2010.07.017. Epub 2010 Aug 7. Biochimie. 2010. PMID: 20696203 Review.
Cited by
-
Targeting Metalloenzymes for Therapeutic Intervention.Chem Rev. 2019 Jan 23;119(2):1323-1455. doi: 10.1021/acs.chemrev.8b00201. Epub 2018 Sep 7. Chem Rev. 2019. PMID: 30192523 Free PMC article. Review.
-
Matrix Metalloproteinase-Deactivating Contact Lens for Corneal Melting.ACS Biomater Sci Eng. 2019 Mar 11;5(3):1195-1199. doi: 10.1021/acsbiomaterials.8b01404. Epub 2019 Jan 4. ACS Biomater Sci Eng. 2019. PMID: 31692998 Free PMC article.
-
Matrix Metalloproteinases as Regulators of Vein Structure and Function: Implications in Chronic Venous Disease.J Pharmacol Exp Ther. 2015 Dec;355(3):410-28. doi: 10.1124/jpet.115.227330. Epub 2015 Aug 28. J Pharmacol Exp Ther. 2015. PMID: 26319699 Free PMC article. Review.
-
Screening chelating inhibitors of HIF-prolyl hydroxylase domain 2 (PHD2) and factor inhibiting HIF (FIH).J Inorg Biochem. 2012 Aug;113:25-30. doi: 10.1016/j.jinorgbio.2012.03.002. Epub 2012 Mar 17. J Inorg Biochem. 2012. PMID: 22687491 Free PMC article.
-
Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.Adv Pharmacol. 2018;81:241-330. doi: 10.1016/bs.apha.2017.08.002. Epub 2017 Sep 19. Adv Pharmacol. 2018. PMID: 29310800 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous